TG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings Results

TG Therapeutics (NASDAQ:TGTX) released its earnings results on Monday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26), Briefing.com reports. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.23%. The business had revenue of $240.34 million for the quarter, compared to analysts’ expectations of $229.77 million. During the same quarter in the previous year, the business posted $0.17 earnings per share. TG Therapeutics’s revenue for the quarter was up 70.2% on a year-over-year basis.

Here are the key takeaways from TG Therapeutics’ conference call:

• BRIUMVI sales exceeded expectations, with U.S. net product revenue of approximately $228 million, up 17% sequentially and more than 64% year over year. TG Therapeutics raised 2026 U.S. revenue guidance to $890 million–$905 million and global revenue guidance to approximately $950 million.
• Commercial momentum remains strong, including record new patient starts, expanding physician adoption, improving persistence, and increasing use in treatment-naive patients. Management expects to exit 2026 at a quarterly U.S. revenue run rate above $250 million, implying its first billion-dollar annualized run rate.
• The company reported positive Phase III ENHANCE results supporting a simplified single-infusion BRIUMVI initiation schedule, potentially available by mid-2027, while its quarterly subcutaneous formulation remains on track for Phase III results around year-end 2026 or early 2027 and could expand the addressable market substantially.
• TG is expanding BRIUMVI beyond relapsing multiple sclerosis, advancing a registration-directed Phase II myasthenia gravis study and a Phase II treatment-resistant schizophrenia study. The azer-cel allogeneic CAR-T program has enrolled more than 20 patients across MS and other B-cell-mediated diseases, with a clinical update expected in the second half of 2026.
• Reported operating income and net income were limited by approximately $55 million of subcutaneous and secondary-source manufacturing charges in the quarter; TG expects about $100 million of such expenses for full-year 2026, in addition to $350 million–$400 million of underlying operating expenses.

TG Therapeutics Stock Up 0.7%

TG Therapeutics stock traded up $0.32 during trading hours on Wednesday, reaching $49.06. The stock had a trading volume of 697,461 shares, compared to its average volume of 2,232,830. The company has a market cap of $7.51 billion, a price-to-earnings ratio of 17.15, a PEG ratio of 1.18 and a beta of 1.62. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $59.30. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The business’s 50 day moving average price is $50.80 and its 200-day moving average price is $39.21.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its holdings in shares of TG Therapeutics by 4.7% during the fourth quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock valued at $252,789,000 after acquiring an additional 379,380 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TG Therapeutics by 35.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after buying an additional 531,759 shares during the last quarter. Invesco Ltd. lifted its position in TG Therapeutics by 47.1% during the fourth quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock valued at $47,989,000 after purchasing an additional 515,481 shares during the period. Man Group plc lifted its holdings in shares of TG Therapeutics by 621.5% in the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after buying an additional 868,697 shares during the period. Finally, Nuveen LLC boosted its stake in shares of TG Therapeutics by 34.1% in the fourth quarter. Nuveen LLC now owns 953,206 shares of the biopharmaceutical company’s stock worth $28,415,000 after buying an additional 242,434 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TGTX shares. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. HC Wainwright reissued a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a research note on Tuesday. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Bank of America raised their price objective on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $58.67.

Trending Headlines about TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: BRIUMVI revenue increased 64% year over year to approximately $228 million, helping TG Therapeutics raise its 2026 BRIUMVI revenue outlook to $950 million from $941.7 million previously expected by analysts. Management said the product remains on track to become a $1 billion U.S. drug. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: HC Wainwright maintained its Buy rating and $78 price target. The analyst raised its fourth-quarter 2026 EPS forecast to $0.37 from $0.31, suggesting expectations for improving near-term profitability. TG Therapeutics analyst estimates
• Neutral Sentiment: Future growth could receive additional support from a subcutaneous version of BRIUMVI, with Phase 3 data expected in late 2026 or early 2027. However, this opportunity remains dependent on clinical and regulatory progress. TG Therapeutics: Why I’m Staying Long After The Q2 Selloff
• Negative Sentiment: Second-quarter EPS was $0.05, missing the $0.31 analyst consensus by $0.26. Although revenue reached $240.34 million and exceeded expectations, manufacturing investments weighed on net income and investors reacted negatively to the earnings quality. TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
• Negative Sentiment: HC Wainwright reduced its EPS estimates for 2026 through 2029: 2026 to $0.86 from $0.99, 2027 to $2.16 from $2.32, 2028 to $3.58 from $3.81, and 2029 to $4.53 from $4.70. The FY2030 estimate also fell to $5.64 from $5.84, signaling lower projected profitability despite the unchanged Buy rating.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.